Opdivo Qvantig
Monoclonal antibody
Evidence outlook
Approved: Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma, Colorectal Cancer, Metastatic Colorectal Cancer, Advanced Colorectal Cancer, Advanced Metastatic Colorectal Cancer, Gastric Cancer, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma, Hepatocellular Carcinoma, Esophageal Squamous Cell Carcinoma
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
Also approved (4)
- Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer OPDIVO QVANTIG, in combination with platinum-doublet chemotherapy, is indicated as neoadjuvant treatment of adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer (NSCLC).
- Neoadjuvant and Adjuvant Treatment of Resectable Non-Small Cell Lung Cancer OPDIVO QVANTIG, in combination with platinum-doublet chemotherapy, is indicated for the neoadjuvant treatment of adult patients with resectable (tumors ≥4 cm or node positive) NSCLC and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements, followed by OPDIVO QVANTIG as monotherapy in the adjuvant setting after surgical resection.
- Adults with unresectable or metastatic hepatocellular carcinoma (HCC) previously treated with sorafenib, following combination treatment with intravenous nivolumab and ipilimumab
- Subcutaneous Opdivo (nivolumab co-formulated with rHuPH20), EU brand Opdivo SC; BMS release dated 28 May 2025; adult solid tumours incl. NSCLC
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Review complete: no registered study met the criteria for featured evidence in this indication.
Its US label bases this use on the trials of intravenous nivolumab (Opdivo), with CheckMate-67T showing comparable drug levels and safety for the subcutaneous form.
0 registry matches · 0 candidates
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Competitive landscape
Other PD-1 drugs
Cemiplimab, Dostarlimab, Nivolumab, Pembrolizumab, Pembrolizumab berahyaluronidase alfa and 21 more. Compare all 27 PD-1 drugs
This mechanism is crowded: 26 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Advanced Colorectal Cancer: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Opdivo Qvantig: this drug | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Iparomlimab (QL1604) | Phase 3(overall) | Monoclonal antibody | PD-1 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| SHR-3045 | Phase 2(overall) | Undisclosed | PD-1 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Bmab1700 | Phase 1(overall) | Monoclonal antibody | PD-1 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Decoy20 | Discontinued | Bacterial immunotherapy | Multiple Toll-like receptors | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
9 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
No upcoming readouts on record for this asset.